Breaking Finance News

Celgene (NASDAQ:CELG) target price reduced to $146.00, issued a report today by UBS

UBS bumped down the target of Celgene (NASDAQ:CELG) to $146.00 stating a potential upside of 0.07%.

Boasting a price of $135.96, Celgene (NASDAQ:CELG) traded -0.88% lower on the day. With the last stock price close up 4.24% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. CELG has recorded a 50-day average of $141.30 and a two hundred day average of $130.43. Trade Volume was up over the average, with 5,700,001 shares of CELG changing hands over the typical 3,710,920

Recent Performance Chart


With a total market value of $0, Celgene has price-earnings ratio of 42.11 with a one year low of $96.93 and a one year high of $147.17 .

A total of 22 brokers have issued a research note on the company. 10 brokers rating the stock a strong buy, 10 brokers rating the stock a buy, 4 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $136.82.

Brief Synopsis On Celgene (NASDAQ:CELG)

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.